Thursday, September 26, 2019 12:09:04 AM
The CEO and management team have actually accomplished quite a bit in the last several months, but these may have been missed. There is likely more to come.
The year started with receiving a new Brilacidin patent, followed by completion of gastric testing supporting development of an oral dosage form to treat IBD, with clinical development then underway. As recently as Sept. 16th the company announced “Successful Formulation of Oral Brilacidin Tablets; Upcoming Clinical Trial to Target Delivery to the Colon.” The trial is expected to start in the Dec. time frame.
In Feb. Leo established a European subsidiary for the company in Ireland and increased his equity stake (late January), and the company received an additional new patent for compounds used to treat oral mucositis using Brilacidin. (mid-February).
The European Medicines Agency granted IPIX a swift meeting after request (only two weeks interim), followed by the company reporting enhancements in manufacturing Brilacidin for a phase 3 study (April 9th).
On May 1st 2019 the company reported receiving the FDA minutes from their end of phase 2 meeting for B-OM held in Dec. 2018.
On May 16th the company announced a non-binding term sheet with a global Pharma to develop Brilacidin for Ulcertaive Proctitis/Proctosigmoiditis, and a few weeks later in early July of this year a first licensing deal with Alfasigma was announced.
On June 6th the company signed an agreement for advanced oral tablet technology with BDD, a company that has a prior and possibly ongoing relationship with Novartis, where President and Chief Medical Officer Arthur Bertolino, MD, PHD, MBA used to work.
At the shareholder meeting a few days ago the increased share authorization passed 150M votes “for” and 14M “against.”
Draw your own conclusions as to why the SP is so low.
Leo has disdained vulture capital, he has not done a reverse split, and reports being in active and ongoing high level negotiations with other pharmas for more licensing deals.
http://www.ipharminc.com/press-release
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM